Answers are grounded in this paper and cite their sources.
Docetaxel (DOC) is a cornerstone in breast cancer chemotherapy, yet its clinical utility is constrained by poor aqueous solubility and systemic toxicity. We report a hybrid nanocarrier that couples an acid-labile zeolitic imidazolate framework-8 (ZIF-8) reservoir with a biocompatible, diffusion-modulating polymer gate composed of sodium alginate (SA)/polyvinylpyrrolidone (PVP) to enable pH-selective, sustained release. The DOC@ZIF-8/SA/PVP composite was synthesized and characterized. XRD confirmed preserved ZIF-8 crystallinity, and FTIR spectra retained characteristic imidazolate bands. Particles showed a unimodal hydrodynamic distribution (hydrodynamic diameter = 184 nm) with a moderately negative zeta potential of −27.6 mV. Nitrogen sorption analysis of pristine ZIF-8 revealed a type I isotherm with a BET surface area of 1171 m 2 /g and a micropore volume of 0.339 cm 3 /g, confirming the highly porous nature of the MOF core used for drug loading. In vitro , the coated system exhibited pH-selective sustained release, reaching 95% at pH 5.5 (96–120 h) versus 59% at pH 7.4 (120 h), whereas bare DOC@ZIF-8 released ≤25% (pH 5.5) and 14% (pH 7.4) over the same window. Release kinetics followed the Korsmeyer-Peppas model, indicating a predominantly Fickian diffusion mechanism. In MCF-7 breast cancer cells and NIH3T3 mouse embryonic fibroblasts, DOC@ZIF-8/SA/PVP showed a therapeutic response window between cancer and normal cells, with lower apparent potency than free DOC in MCF-7 cells and reduced toxicity toward NIH3T3 fibroblasts. These findings indicate that the polymer-gated ZIF-8 system improves controlled, pH-selective DOC delivery while reducing normal-cell toxicity, rather than increasing DOC's intrinsic potency. The integration of an MOF reservoir with a polymer gate enables pH-responsive, sustained release of DOC, thereby improving controlled delivery and maintaining biocompatibility in vitro . Overall, the MOF reservoir/polymer gate formulation provides a promising platform for pH-selective DOC delivery and warrants further in vivo evaluation of pharmacokinetics, biodistribution, antitumor efficacy, and safety.
No takes yet. Share an insight, caveat, or question.
Asadi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: